IL276813B2 - 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES - Google Patents

4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES

Info

Publication number
IL276813B2
IL276813B2 IL276813A IL27681320A IL276813B2 IL 276813 B2 IL276813 B2 IL 276813B2 IL 276813 A IL276813 A IL 276813A IL 27681320 A IL27681320 A IL 27681320A IL 276813 B2 IL276813 B2 IL 276813B2
Authority
IL
Israel
Prior art keywords
compound
group
additional therapeutic
therapeutic agent
combination
Prior art date
Application number
IL276813A
Other languages
English (en)
Hebrew (he)
Other versions
IL276813A (en
IL276813B1 (en
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of IL276813A publication Critical patent/IL276813A/en
Publication of IL276813B1 publication Critical patent/IL276813B1/en
Publication of IL276813B2 publication Critical patent/IL276813B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL276813A 2018-03-05 2019-03-04 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES IL276813B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638412P 2018-03-05 2018-03-05
PCT/US2019/020507 WO2019173188A1 (en) 2018-03-05 2019-03-04 Arginase inhibitors

Publications (3)

Publication Number Publication Date
IL276813A IL276813A (en) 2020-10-29
IL276813B1 IL276813B1 (en) 2024-05-01
IL276813B2 true IL276813B2 (en) 2024-09-01

Family

ID=67847429

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276813A IL276813B2 (en) 2018-03-05 2019-03-04 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES

Country Status (21)

Country Link
US (1) US12054500B2 (enExample)
EP (1) EP3761992A4 (enExample)
JP (1) JP7402167B2 (enExample)
KR (1) KR102656571B1 (enExample)
CN (1) CN111818928A (enExample)
AU (1) AU2019229978B2 (enExample)
BR (1) BR112020017604A2 (enExample)
CA (1) CA3091805A1 (enExample)
CL (1) CL2020002271A1 (enExample)
CO (1) CO2020012060A2 (enExample)
CR (1) CR20200445A (enExample)
EA (1) EA202092086A1 (enExample)
IL (1) IL276813B2 (enExample)
MX (1) MX2020009290A (enExample)
MY (1) MY205512A (enExample)
PE (1) PE20210452A1 (enExample)
PH (1) PH12020551352A1 (enExample)
SG (1) SG11202008113RA (enExample)
UA (1) UA127897C2 (enExample)
WO (1) WO2019173188A1 (enExample)
ZA (1) ZA202006006B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530240B2 (en) * 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
EP3810615B1 (en) * 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
EP3880685B1 (en) 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
EP3897622B1 (en) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
TW202421150A (zh) 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4788432A1 (en) 2023-10-06 2026-08-12 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058065A1 (en) * 2010-10-26 2012-05-03 Mars Incorporated Boronates as arginase inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
BR0210149A (pt) 2001-05-09 2004-06-29 Newbiotics Inc Pródrogas ativadas por deformilase de peptìdeo
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102292319A (zh) 2008-11-26 2011-12-21 雅培制药有限公司 作为钙通道阻滞剂的取代八氢环戊二烯并(c)吡咯-4-胺
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
RU2488390C2 (ru) 2008-12-29 2013-07-27 Тартуский Университет Ингибиторы аргиназы для лечения депрессии
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104540836B (zh) 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP3008051A4 (en) 2013-06-12 2017-03-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9663491B2 (en) 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CL2014002403A1 (es) 2014-09-11 2015-01-09 Univ Pontificia Catolica Chile Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion.
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
WO2016100555A1 (en) 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
EP3810615B1 (en) 2018-06-20 2026-01-28 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058065A1 (en) * 2010-10-26 2012-05-03 Mars Incorporated Boronates as arginase inhibitors

Also Published As

Publication number Publication date
ZA202006006B (en) 2025-02-26
UA127897C2 (uk) 2024-02-07
CO2020012060A2 (es) 2021-01-18
PE20210452A1 (es) 2021-03-08
CA3091805A1 (en) 2019-09-12
CL2020002271A1 (es) 2021-04-09
EP3761992A1 (en) 2021-01-13
JP2021516237A (ja) 2021-07-01
KR20200128117A (ko) 2020-11-11
AU2019229978A1 (en) 2020-10-15
MX2020009290A (es) 2020-09-28
CR20200445A (es) 2021-04-27
KR102656571B1 (ko) 2024-04-11
US12054500B2 (en) 2024-08-06
AU2019229978B2 (en) 2024-05-30
US20210002306A1 (en) 2021-01-07
MY205512A (en) 2024-10-24
CN111818928A (zh) 2020-10-23
WO2019173188A1 (en) 2019-09-12
JP7402167B2 (ja) 2023-12-20
IL276813A (en) 2020-10-29
EA202092086A1 (ru) 2021-02-09
SG11202008113RA (en) 2020-09-29
BR112020017604A2 (pt) 2020-12-22
IL276813B1 (en) 2024-05-01
PH12020551352A1 (en) 2021-06-21
EP3761992A4 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
IL276813B1 (en) 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES
JP2021516237A5 (enExample)
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EA200700902A1 (ru) 3-ариламинопиридиновые производные
JP2020519664A5 (enExample)
Liu et al. Platinum-based modification of styrylbenzylsulfones as multifunctional antitumor agents: targeting the RAS/RAF pathway, enhancing antitumor activity, and overcoming multidrug resistance
EA201290237A1 (ru) Киназные ингибиторы
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
NZ600042A (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
UA107100C2 (xx) Конденсовані гетероароматичні піролідинони як інгібітори syk
CN1298305A (zh) 白介素－6产生抑制剂
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
Yan et al. Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: design, synthesis, inhibitory activity and 3D-QSAR analysis
MX2023004937A (es) Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.
Guo et al. Research progress on Small-molecule inhibitors of protein arginine methyltransferase 5 (PRMT5) for treating cancer
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
Park et al. Potential therapeutic targets in ovarian cancer: autophagy and metabolism
Xu et al. Azo-based hypoxic-activated 6-diazo-5-oxo-L-norleucine (DON) prodrug combined with vascular disrupting agent nanoparticles for tumor-selective glutamine metabolism blockade
Ueno et al. Antitumor effect of a novel phenanthroindolizidine alkaloid derivative through inhibition of protein synthesis
US20230135822A1 (en) Adenosine analogs as methyltransferase inhibitors for treating cancer
US20090270397A1 (en) Methods and compositions for the treatment of cancers, such as melanomas and gliomas
EA202092291A1 (ru) Соединение на основе хинолина или хиназолина и его применение
Gutiérrez et al. Epigenetic modulators as treatment alternative to diverse types of cancer